Curated News
By: NewsRamp Editorial Staff
September 14, 2026
Telomir-Zn Shows Promise in Osteosarcoma; TNBC Program Advances
TLDR
- Telomir Pharmaceuticals' Telomir-Zn shows growth inhibition in osteosarcoma models, offering a potential first-mover advantage in a new cancer indication.
- Telomir-Zn was tested on one human and two canine osteosarcoma cell lines, demonstrating growth inhibition at low drug concentrations.
- Telomir Pharmaceuticals' research on Telomir-Zn for osteosarcoma could lead to new treatments for both dogs and humans, improving lives.
- Telomir Pharmaceuticals found that Telomir-Zn inhibits osteosarcoma cell growth, and they are exploring a canine study that could help humans too.
Impact - Why it Matters
<p>This news matters because it highlights a potential new therapeutic avenue for osteosarcoma, a rare and aggressive bone cancer that primarily affects children and young adults. Current treatment options for osteosarcoma are limited, often involving surgery and chemotherapy with significant side effects. The finding that Telomir-Zn inhibits growth in both human and canine osteosarcoma cell lines at low concentrations suggests a possible dual-benefit approach: developing a veterinary treatment for dogs with naturally occurring osteosarcoma while simultaneously gathering translational data that could accelerate human clinical trials. This comparative oncology strategy is increasingly recognized as a valuable tool to de-risk oncology drug development. Moreover, Telomir’s ongoing Phase 1/2 trial in triple-negative breast cancer—a particularly difficult-to-treat form of breast cancer—demonstrates the company’s broader commitment to addressing unmet needs in oncology. For investors, these developments could signal multiple shots on goal within a single pipeline, potentially increasing the chances of clinical and commercial success.</p>
Summary
Telomir Pharmaceuticals (NASDAQ: TELO) has announced promising new research findings from The Ohio State University College of Veterinary Medicine showing that its lead drug candidate, Telomir-Zn, inhibited growth across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study, led by Shay Bracha, DVM, MS, DACVIM (Oncology), evaluated Telomir-Zn in one human and two canine osteosarcoma models. These results support further translational investigation and a potential development pathway using naturally occurring canine osteosarcoma as a model for human disease.
Telomir is currently in discussions with The Ohio State University College of Veterinary Medicine to assess next steps for a potential in vivo efficacy study in canine osteosarcoma. Such a study could support both veterinary development and translational advancement toward human osteosarcoma. However, the company emphasized that its immediate focus remains its triple-negative breast cancer program, which is advancing toward site initiation and Phase 1/2 patient enrollment under an active FDA-cleared Investigational New Drug (IND) application for advanced or metastatic TNBC.
Telomir Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. Its lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation. The company’s news is distributed through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. For investors, the latest updates on TELO are available in the company’s newsroom at https://nnw.fm/TELO. To view the full press release, visit https://nnw.fm/laeGH.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Telomir-Zn Shows Promise in Osteosarcoma; TNBC Program Advances
